Proteomics and Mass Spectrometry for Cancer Biomarker Discovery

  • Lu M
  • Faull K
  • Whitelegge J
  • et al.
N/ACitations
Citations of this article
52Readers
Mendeley users who have this article in their library.

Abstract

Proteomics is a rapidly advancing field not only in the field of biology but also in translational cancer research. In recent years, mass spectrometry and associated technologies have been explored to identify proteins or a set of proteins specific to a given disease, for the purpose of disease detection and diagnosis. Such biomarkers are being investigated in samples including cells, tissues, serum/plasma, and other types of body fluids. When sufficiently refined, proteomic technologies may pave the way for early detection of cancer or individualized therapy for cancer. Mass spectrometry approaches coupled with bioinformatic tools are being developed for biomarker discovery and validation. Understanding basic concepts and application of such technology by investigators in the field may accelerate the clinical application of protein biomarkers in disease management.

Cite

CITATION STYLE

APA

Lu, M., Faull, K. F., Whitelegge, J. P., He, J., Shen, D., Saxton, R. E., & Chang, H. R. (2007). Proteomics and Mass Spectrometry for Cancer Biomarker Discovery. Biomarker Insights, 2, 117727190700200. https://doi.org/10.1177/117727190700200005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free